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THE COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS SIMVASTATIN 
FOR THE PREVENTION OF CARDIOVASCULAR MORBIDITY AND 
MORTALITY IN PATIENTS WITH HIGH BASELINE RISK—A SWEDISH 
ECONOMIC EVALUATION BASED UPON THE JUPITER TRIAL
Olsson AG1, Jensen MM2, Gandhi SK3, Smolen L4, Paulsson T5
1Linköping University Sweden, Linköping, Sweden; 2AstraZeneca, Lund, Sweden; 
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USA; 5AstraZeneca Nordic MC, Södertälje, Sweden
OBJECTIVES: To assess the long-term cost-effectiveness of various doses of rosuvas-
tatin (R) versus relevant doses of simvastatin (S) (R20 mg versus S40 mg (primary 
analysis), R10 versus S20 and R10 versus S40) in a patient population with high risk 
of cardiovascular events (10-year Framingham CVD risk ≥ 20%). METHODS: A 
Monte Carlo simulation model was developed based on the JUPITER (Justiﬁ cation 
for the Use of statins in Primary prevention: an Intervention Trial evaluating Rosuv-
astatin, NCT00239681) trial ﬁ ndings and includes modeling of cardiovascular events 
and death over the lifetime of patients. The relative efﬁ cacy of S20, S40 and R10 
compared with R20 (as observed in JUPITER) was estimated by computing relative 
10-year Framingham cardiovascular event risks based on reported differences in Total 
Cholesterol/High-Density Lipoprotein cholesterol ratio. Epidemiological data speciﬁ c 
for the Swedish setting were utilized to model post-event mortality and long-term 
overall mortality in event-free patients. Incremental effectiveness was primarily mea-
sured as quality-adjusted life-years (QALYs) gained. Cost-effectiveness was assessed 
based upon direct costs. All effects and costs (in 2008/09 Swedish unit prices) were 
discounted at annual 3%. RESULTS: The model estimated that treating a cohort of 
100,000 patients (66 years, 60% males) with R20 mg avoided 2642 CVD events over 
lifetime compared with S40 mg. This translated into an estimated gain of 9515 years 
in full health (QALYs). The incremental cost per QALY gained was SEK161,712 
(16,434). The cost per QALY gained was SEK228,655 (c23,237) for R10 versus S20, 
and SEK234,932 (c23,875) for R10 versus S40. Probabilistic sensitivity analyses sup-
ported base-case results. CONCLUSIONS: Treatment with rosuvastatin 10 and 20 mg 
is cost-effective compared with relevant doses of simvastatin in the primary prevention 
of CVD for patients with high baseline cardiovascular risk (10-year Framingham CVD 
risk ≥ 20%).
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THE COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS 
ATORVASTATIN FOR THE PREVENTION OF CARDIOVASCULAR 
MORBIDITY AND MORTALITY IN PATIENTS WITH HIGH BASELINE 
RISK—A SWEDISH ECONOMIC EVALUATION OF THE JUPITER TRIAL
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OBJECTIVES: To assess long-term cost-effectiveness of various doses of rosuvastatin 
(R) versus relevant doses of generic atorvastatin (A) (R20 mg versus A40 mg (primary 
comparison), R10 versus A20 and; R40 versus A80) in patients with a high risk of 
CV events (10-year Framingham CVD risk ≥ 20%). METHODS: A Monte Carlo 
simulation model was developed based on JUPITER (Justiﬁ cation for the Use of statins 
in Primary prevention: an Intervention Trial evaluating Rosuvastatin, NCT00239681) 
trial ﬁ ndings and modeled cardiovascular events and death over the lifetime of 
patients. The relative efﬁ cacy of the A20, A40, A80, R10, and R40 mg compared to 
R20 mg (as observed in JUPITER) were estimated by computing relative 10-year 
Framingham cardiovascular event risks based on reported differences in Total Cho-
lesterol/High-Density Lipoprotein cholesterol ratio. Epidemiological data speciﬁ c for 
the Swedish setting were utilized to model mortality. Incremental effectiveness was 
primarily measured as quality-adjusted life-years (QALYs) gained. Cost-effectiveness 
was assessed based upon direct costs. All effects and costs (2008/09 Swedish unit 
prices) were discounted at annual 3%. An 80% price reduction was assumed for 
generic versus branded statin. RESULTS: The model estimated that treating a cohort 
of 100,000 patients (66 years, 60% males) with R20 avoided 1121 CVD events over 
lifetime compared with atorvastatin 40 mg. This translated into an estimated gain of 
4090 years in full health (QALYs). The estimated incremental cost per QALY gained 
was SEK366,763 (c37,273). This estimate was SEK428,060 (c43,502) for R10 versus 
A20, and SEK582,241 (c59,171) for R40 versus A80. Probabilistic sensitivity analyses 
supported base-case results. CONCLUSIONS: Treatment with rosuvastatin 10 mg, 
20 mg and 40 mg is cost-effective compared with relevant doses of generic atorvastatin 
(20 mg, 40 mg, 80 mg, respectively) for the primary prevention of cardiovascular 
events for patients with high baseline cardiovascular risk (10-year Framingham CVD 
risk ≥ 20%) in Sweden.
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1The University of Melbourne, Fitzroy, Victoria, Australia; 2Pﬁ zer Limited, Surrey, UK; 3Pﬁ zer, 
Bruxelles, Belgium
OBJECTIVES: Containing pharmaceutical budgets has encouraged generic prescribing 
policies. Across Europe, many patients have been switched from atorvastatin to 
generic statins, particularly simvastatin, but often at lower therapeutic doses. This 
study sought to estimate the potential clinical and economic effect if policy-induced 
switching to ﬁ rst generation statins occurred in Belgium as per previously observed 
patterns. METHODS: A Markov micro-simulation model was populated with 80 
primary prevention Belgian patients from a 2007 observational study. Risks of ﬁ rst-
onset cardiovascular disease (CVD) were estimated using a calibrated Framingham 
risk equation. With a baseline of January 2010, follow-up was simulated for 20 years. 
Decision analysis estimated the marginal effects of switching all patients from atorv-
astatin (weighted average daily dose [WADD] 20.7 mg) to simvastatin (WADD 
31.6 mg). Dose-speciﬁ c, lipid-modifying effects of the two statins, CVD costs and 
utilities were sourced from published data. Annual discount rates of 3% and 1.5% 
were applied to costs and health effects, respectively. RESULTS: Of the 80 subjects 
on atorvastatin, 23 (28.9%) were predicted to develop CVD over 20 years. In the 
switched-to-simvastatin group, the predicted number was 26 (32.0%), equating to a 
“number needed to harm” of 32. Switching was estimated to lead to a net cost saving 
of c581 per subject, but also a loss of 0.04 QALYs. These equated to an ICER of 
c13,608 per QALY gained (atorvastatin vs. simvastatin). Sensitivity analyses indicated 
the results to be robust. CONCLUSIONS: Our preliminary analyses indicate that there 
would be an increase in the burden of CVD if Belgian patients are switched from 
atorvastatin to generic simvastatin at non-equipotent doses, as has happened in neigh-
bouring countries like The Netherlands. This study highlights the need to consider the 
potential health and health economic impact of population-based switching policies.
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THROMBOPROPHYLAXIS AFTER TOTAL KNEE REPLACEMENT: 
COST-UTILITY ANALYSIS OF RIVAROXABAN VERSUS ENOXAPARIN IN 
SLOVAKIA
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OBJECTIVES: To estimate the cost-effectiveness of rivaroxaban against enoxaparin 
for the prophylaxis of venous thromboembolism (VTE) in patients after total knee 
replacement (TKR) in Slovakia from payer perspective. METHODS: Previously pub-
lished cost-utility model based on results of large randomized controlled trial 
(RECORD 3) has been adapted to Slovakian settings. In RECORD 3, patients received 
12 days prophylaxis with rivaroxaban or enoxaparin. Rivaroxaban reduced total VTE 
(composite: any DVT, non-fatal PE, all-cause mortality) by 49% versus enoxaparin 
after 12 days prophylaxis. The model was divided into three parts: prophylaxis, post-
prophylaxis, and long-term complications. The ﬁ rst two parts represents acute phase 
and were modeled as a decision tree. Third part represents the long-term complications 
and was developed as a Markov model. The ﬁ rst part of the model is populated by 
RECORD 3 trial, while published epidemiological and clinical data estimating the risk 
of further VTE events and post-thrombotic syndrome beyond the trial period were 
used in second and third part of the model. Local cost data was based on published 
price lists, clinical guidelines, product labels and expert opinion. VTE related utilities 
were used from literature. Effectiveness was measured in quality-adjusted life-years 
(QALY). Time horizon was set at 5 years and payers perspective was used. Discount 
rate was 5% per year for costs and effects according to valid Ministry of Health 
(MoH) guidelines for health economic evaluation. One-way and probabilistic sensitiv-
ity analyses were performed. RESULTS: Rivaroxaban produced improved outcomes 
(QALY) and cost savings of c28 per patient versus enoxaparin in Slovakian setting 
(dominance). Probabilistic sensitivity analysis showed dominance of rivaroxaban com-
pared to enoxaparin in more then 99% of cases. CONCLUSIONS: Prophylaxis of 
VTE with rivaroxaban following TKR may improve health outcomes and reduce direct 
medical costs when compared to enoxaparin in Slovakian setting.
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POTENTIAL COST-EFFECTIVENESS OF A BIOMARKER TEST TO 
STRATIFY PATIENTS INDICATED FOR A CORONARY STENT
Burgers LT, Redekop WK, Severens JL
Erasmus University Rotterdam, Rotterdam, The Netherlands
OBJECTIVES: Patients requiring a coronary stent can receive a bare-metal stent (BMS) 
or a drug-eluting stent (DES), but both have their advantages and disadvantages. We 
estimated the potential one-year cost-effectiveness of a test to decide which stent a 
patient should receive based on the risk of restenosis after a BMS implantation. 
METHODS: This study was performed as part of a Dutch large-scale ﬁ ve-year study 
(“Circulating Cells”) now underway to identify blood biomarkers to facilitate the 
prevention and treatment of coronary heart disease. a Markov chain Monte Carlo 
model was developed to estimate costs and effectiveness for three strategies: DES for 
all patients, BMS for all patients, and use of a test (80% sensitivity & 80% speciﬁ city). 
Input values were based on the literature and expert opinion. Costs were calculated 
according to the health care sector perspective. Scenario and sensitivity analyses were 
performed to test the robustness of the results. RESULTS: The DES-for-all strategy 
was the most effective (0.840 QALYs), followed by the test strategy (0.839) and the 
BMS-for-all strategy (0.838). However, it was also more costly (c8189) than the other 
two (test strategy, c7475; BMS, c6905). These results meant high incremental cost-
effectiveness ratios for the test and DES-for-all strategies. Implanting DES in all 
patients would have an important budget impact (c46,000,000) for the The Nether-
lands, given 36,000 interventions annually. Various input parameters had an impor-
tant inﬂ uence on the results, including the sensitivity, speciﬁ city and costs of the test. 
CONCLUSIONS: Both DES and BMS stents are often used for PCIs in the The 
Netherlands. a stratifying test has the potential to reduce costs and still achieve accept-
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able effects. The impact of adopting a longer time horizon to capture very late stent 
thrombosis needs to be examined. The model developed in this study will be used to 
facilitate further development of the biomarker test.
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ECONOMIC EVALUATION OF LIFESTYLE INTERVENTION IN PRIMARY 
PREVENTION OF CARDIOVASCULAR DISEASE IN 60-YEAR-OLD MEN IN 
STOCKHOLM, SWEDEN
Saha S1, Lindgren P2, Johansson P2, Gerdtham UG1
1Lund University, Lund, Sweden; 2Karolinska Institute, Stockholm, Sweden
OBJECTIVES: To assess the cost utility analysis of lifestyle interventions (diet, physi-
cal activity and diet + physical activity) at primary care for person with high risk of 
cardiovascular disease by using a Markov model. METHODS: A cost-utility analysis 
was performed using a 10-state Markov model of CVD (cardiovascular disease) events 
applied to a cohort of 60 year-old men from the county of Stockholm, Sweden. a 
previously performed randomized controlled trial of dietary advice, physical exercise 
and diet + physical exercise on middle aged men of Sweden (The Sollentuna study) 
was used as effectiveness of intervention. The risk of having a CVD event in primary 
care was taken from The Framingham Heart Study. Lifetime costs and health effects 
(QALYs, quality-adjusted life-years) were estimated, in both a health care and societal 
perspective with 3% discount rate. RESULTS: The model predicts physical exercise 
to be the best option at zero willingness to pay and dietary advice the best if the 
decision-maker willingness to pay is higher than 60,000 SEK per QALY (1 Euro = 
10.74 SEK (2009). The incremental cost-effectiveness ratio (ICER), compared with no 
intervention is 77,000 SEK/ QALY from a health care perspective and 57,000 SEK/
QALY from a societal perspective. CONCLUSIONS: Based on the model estimates, 
dietary advice and physical exercise both are cost-effective interventions, and the 
choice depends upon the decision-maker willingness to pay.
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PRIORITIZING FURTHER RESEARCH USING THE EXPECTED VALUE OF 
PERFECT INFORMATION: APPLICATION TO VENOUS 
THROMBOEMBOLISM PROPHYLAXIS POST TOTAL HIP REPLACEMENT
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OBJECTIVES: To estimate the expected value of perfect information (EVPI) associ-
ated with a lifetime Markov-model which evaluated the cost-effectiveness of rivaroxa-
ban and dabigatran compared to enoxaparin for venous thromboembolism (VTE) 
prophylaxis after total hip replacement (THR). To estimate the expected value of 
perfect parameter information (EVPPI). To indentify the model parameter subset 
whose uncertainty drives the decision uncertainty. To decrease the uncertainty, by 
collecting additional data on this subset. To investigate the impact of threshold change 
on the EVPI/EVPPI values. METHODS: EVPI was determined directly from PSA and 
was calculated over the threshold c0–100,000/QALY. Population EVPI (PEVPI) was 
calculated based on the 5464 THR procedures performed in Ireland in 2006 and the 
ENDORSE-study which revealed that 64% of at risk surgical patients in Ireland 
receive recommended VTE prophylaxis. The assumptions were; a 50% policy of 
choice uptake rate, a 4% discount rate and a 10-year time horizon. Alternative 
assumptions of 5 and 15 years were explored. EVPPI were calculated for the 3 param-
eter subsets using the 2-stage Monte-Carlo algorithm. RESULTS: Base-case analysis 
indicated that rivaroxaban dominated. Probabilistic analysis (PSA) indicated that at 
c45,000/QALY, the probability that rivaroxaban was the most cost-effective strategy 
was 67%. The PEVPI was c15.62 million. Costs had the highest EVPPI (c12.43 
million), followed by probabilities (c1.45 million) and preference weights (c1.44 
million). The costs subset was most sensitive to threshold. Costs were updated with 
a more detailed costing study. All analyses were repeated. Base-case analysis indicated 
that rivaroxaban continued to dominate. The probability that rivaroxaban was the 
most cost-effective strategy increased to 81%. PEVPI decreased to c4.59 million. 
EVPPI for costs decreased to c2.13 million. EVPPI for probabilities and preference 
weights were c1.03 million and c0.94 million respectively. CONCLUSIONS: This 
study demonstrates the application of EVPI/EVPPI analyses to quantify and decrease 
uncertainty associated with the choice of VTE prophylaxis after THR in the Irish 
health care setting. 
CARDIOVASCULAR DISORDERS – Patient-Reported Outcomes Studies
PCV97
AN EVALUATION OF ONCE- VERSUS TWICE-DAILY DOSING ON 
PERSISTENCE WITH PRESCRIPTION MEDICATIONS IN 
CARDIOVASCULAR PATIENTS
Bae JP1, Zagar A1, Dobesh PP2, Klepser DG2, Anderson J1, Tomlin ME1, McCollam PL1
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OBJECTIVES: To compare patient persistence with chronic-use prescription medica-
tions between once- (QD) and twice-daily (BID) dosing. METHODS: Using a large 
claims database (MarketScan), prescription medications were deﬁ ned as QD if ≥80% 
of claims showed a quantity/day = 1 and as BID if ≥80% of claims had a quantity/
day = 2. Data for patients (18 years or older) with a ﬁ rst claim in 2007 were selected 
for analysis and were further limited to 4 classes of medications frequently used by 
cardiovascular patients: antiplatelet, general cardiac, antihyperlipidemic, or antidia-
betic medications. Persistence was measured by time-to-discontinuation (TTD), 
deﬁ ned as the number of days from the ﬁ rst prescription ﬁ lled to the ﬁ rst gap of >30 
days between exhausting the supplied medication and ﬁ lling the next prescription. The 
mean TTD with censoring at 365 days was estimated. a proportional hazards model 
accounting for within-patient correlations in patients using multiple medications was 
used to model the TTD. The model was stratiﬁ ed on medication class and adjusted 
for baseline confounding variables (gender, age, Charlson Comorbidity Index). 
RESULTS: A total of 1,077,936 patients were included, and the number of patient-
medication combinations was 1,440,917 (QD: 1,384,565 and BID: 56,352). The 
estimated mean TTD for BID compared to QD was −8% overall (P < 0.01) and −32% 
for antiplatelet agents (P < 0.01), −22% for antihyperlipidemic agents (P < 0.01), 
−10% for antidiabetic agents (P < 0.01), and 1% for cardiac agents (P < 0.05). 
CONCLUSIONS: In this unique, recent, claims analysis, investigating multiple thera-
peutic classes of medications in a large database, persistence with antidiabetic, anti-
hyperlipidemic, and antiplatelet agents was greater with QD compared with BID 
dosing; however, a wide range in the differences in persistence between QD and BID 
dosing was noted between therapeutic classes. Persistence may prevent subsequent 
adverse events.
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IMPACT OF MEDICATION ADHERENCE ON HEALTH CARE 
EXPENDITURES BY MEDICARE BENEFICIARIES WITH HEART FAILURE
Lopert R1, Shoemaker JS2, Stuart B3, Davidoff A3, Shaffer T3, Lloyd J2
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OBJECTIVES: Various studies have sought to determine the impact of medication 
adherence on medical expenditure among the elderly with chronic conditions. To date, 
none have looked explicitly at adherence to treatment in cardiac failure, a common 
condition in the elderly. This study had two aims: 1) to measure adherence to treat-
ment for recommended heart failure medications, and 2) to assess whether better 
adherence is associated with lower spending among Medicare beneﬁ ciaries. 
METHODS: We used data from the 1997–2005 Medicare Current Beneﬁ ciary Survey 
to track utilization rates for cardiac failure medications over three years in a nation-
ally-representative sample of Medicare beneﬁ ciaries. The relationship between MPR 
and Medicare costs was tested in a sequence of multivariate models with extensive 
behavioral variables to control for healthy adherer bias and reverse causality. 
RESULTS: Over 3 years, median MPR values were 0.77 for ACE-I/ARB users, 0.74 
for beta blockers, 0.82 for diuretics and 0.74 for cardiac glycosides. Higher adherence 
rates were consistently associated with lower Medicare spending in every model tested. 
The estimated marginal effect of a 10 point increase in MPR for an ACE-I or ARB 
was a reduction in cumulative 3-year Medicare spending of $390 (P < 0.05) in 2006 
dollars. Similar increases in MPRs for beta blocker, diuretics, and cardiac glycosides 
were associated with $861 (P < 0.01), $520 (P < 0.01) and $2318 (P < 0.01) in lower 
Medicare costs respectively over three years. CONCLUSIONS: Higher levels of adher-
ence to recommended CHF regimens by Medicare beneﬁ ciaries were associated with 
lower cumulative Medicare spending over three years, with savings generally exceed-
ing the cost of the drugs.
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COMPLIANCE AND PERSISTENCE WITH ANTIHYPERTENSIVES IN THE 
NETHERLANDS; A COMPARATIVE ANALYSIS WITH SPECIFIC FOCUS 
ON RAAS INTERVENING AGENTS
Vegter S, Visser ST, Boersma C, Postma MJ
University of Groningen, Groningen, The Netherlands
OBJECTIVES: Inaccurate use of chronic medication is associated with worse disease 
prognosis and high health care costs. Differences in drug prices might be outweighted 
by differences in costs due to compliance and persistence. The aim of this study was 
to investigate compliance and persistence with antihypertensive agents acting on the 
renin-angiotensin-aldosterone-system (RAAS). METHODS: A cohort study was con-
ducted based on pharmacy dispensing records (IADB.nl). Subjects were included who 
initiated treatment with either ACE-inhibitors (ACEi) or angiotensin receptor blockers 
(ARBs) between 1999 and 2007. a standardized toolbox was used, Reﬁ ll-Sequence 
analyses (RS) measured persistence; Proportion of Days Covered analyses (PDC) 
measured one-year compliance. Differences in persistence were adjusted for age, 
gender and time of treatment initiation. RESULTS: A total of 27,544 patients initiated 
treatment with ACEi; 8,649 patients initiated treatment with ARBs. Using a grace 
period of 60 days, persistence with ARBs was better compared to ACEi, adjusted HR: 
0.90 (95%CI: 0.84–0.96). Using a PDC cutpoint of 80%, one-year compliance with 
ARBa was also better compared to ACEi, 83.9% vs. 86.3%, P < 0.01. Within ACEi’s, 
differences in persistence between drugs were small. Within ARBs, persistence with 
losartan or valsertan was higher compared to irbesartan or candesartan, adjusted HR: 
0.82 (0.74–0.90). Compliance within ARBs however was similar for all drugs (P = 
0.27). Results were consistent when other grace periods or PDC cutpoints were used. 
CONCLUSIONS: Chronic users of ARBs were more compliant and persistent com-
pared to users of ACEi. Differences in persistence within ARBs might be due to dif-
ferences in drug tolerability and safety, but also due to differences in drug indications. 
Further results will be presented further exploring these ﬁ ndings, as well as analyzing 
differences in persistence between branded versus generic ACEi.
